<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00010127</url>
  </required_header>
  <id_info>
    <org_study_id>0759</org_study_id>
    <secondary_id>DUMC-000759-00-4R1</secondary_id>
    <secondary_id>DUMC-DORIS-99043</secondary_id>
    <secondary_id>NCI-G00-1910</secondary_id>
    <secondary_id>CDR0000068447</secondary_id>
    <nct_id>NCT00010127</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer</brief_title>
  <official_title>A Safety and Feasibility Study of Active Immunotherapy in Patients With Metastatic Prostate Carcinoma Using Autologous Dendritic Cells Pulsed With Antigen Encoded in Amplified Autologous Tumor RNA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune&#xD;
      response to kill prostate tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who&#xD;
      have metastatic prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and feasibility of autologous dendritic cells transfected with&#xD;
           autologous total tumor RNA in patients with metastatic prostate cancer.&#xD;
&#xD;
        -  Determine the presence, frequency, and activation status of tumor specific and prostate&#xD;
           specific antigen (PSA) specific cellular immune responses in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine delayed-type hypersensitivity reactions to PSA protein and other recall&#xD;
           antigens in patients before and after being treated with this regimen.&#xD;
&#xD;
        -  Determine clinical responses based on clinical and biochemical (PSA) response criteria&#xD;
           in patients treated with this regimen.&#xD;
&#xD;
        -  Determine a platform for immunological treatment using dendritic-cell based tumor&#xD;
           vaccines in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study.&#xD;
&#xD;
      Tumor tissue and peripheral blood stem cells are collected from patients and cultured in&#xD;
      vitro with sargramostim (GM-CSF) and interleukin-4 for 7 days to produce dendritic cells&#xD;
      (DC). Patients receive autologous DC transfected with autologous prostate carcinoma RNA&#xD;
      intradermally once weekly on weeks 0-3 for a total of 4 doses.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of DC until the maximum tolerated dose (MTD)&#xD;
      is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at weeks 6, 8, 10, and 12; every 3 months for 9 months; and then&#xD;
      annually for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18 patients will be accrued for this study within 20 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>November 2000</start_date>
  <completion_date type="Actual">March 2003</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">3</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous dendritic cells</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic adenocarcinoma of the prostate&#xD;
&#xD;
               -  Stage D1-3&#xD;
&#xD;
               -  Regional lymph node, bone, visceral, or soft tissue metastases&#xD;
&#xD;
               -  No transitional cell or small cell carcinoma&#xD;
&#xD;
          -  Testosterone less than 50 mg/L if prior treatment with luteinizing hormone releasing&#xD;
             hormone (LHRH) analogues or estrogens&#xD;
&#xD;
          -  Evidence of androgen refractory disease after surgical castration and discontinuation&#xD;
             of LHRH analogue therapy&#xD;
&#xD;
          -  No previously irradiated or new CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  PT at least 11.3 seconds but no greater than 13.3 seconds&#xD;
&#xD;
          -  PTT at least 20.1 seconds but no greater than 32.9 seconds&#xD;
&#xD;
          -  No hepatic disease&#xD;
&#xD;
          -  No viral hepatitis&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No asthma&#xD;
&#xD;
          -  No chronic obstructive pulmonary disease&#xD;
&#xD;
          -  No severe lung disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other medical illness or psychological impediment that would preclude study&#xD;
&#xD;
          -  No other concurrent malignancy except nonmelanoma skin cancer or controlled&#xD;
             superficial bladder cancer&#xD;
&#xD;
          -  No active acute or chronic infection including symptomatic urinary tract infection&#xD;
&#xD;
          -  No autoimmune disease (e.g., inflammatory bowel disease, systemic lupus erythematosus,&#xD;
             rheumatoid arthritis, ankylosing spondylitis, scleroderma, or multiple sclerosis)&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Adequate peripheral vein access&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Prior biologic therapy allowed&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Prior chemotherapy allowed&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior non-steroidal hormonal therapy if increase in PSA while&#xD;
             receiving non-steroidal hormonal therapy&#xD;
&#xD;
          -  At least 6 weeks since prior steroids&#xD;
&#xD;
          -  Concurrent LHRH analogues for gonadal androgen suppression allowed&#xD;
&#xD;
          -  No concurrent steroid therapy&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior palliative radiotherapy for bone metastases allowed&#xD;
&#xD;
          -  Prior prostatic radiotherapy allowed&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  At least 12 weeks since prior strontium chloride Sr 89&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  No concurrent immunosuppressive agents (e.g., azathioprine or cyclosporine)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Vieweg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>February 2, 2001</study_first_submitted>
  <study_first_submitted_qc>July 29, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2003</study_first_posted>
  <last_update_submitted>March 19, 2013</last_update_submitted>
  <last_update_submitted_qc>March 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

